Join BOPA
Back to news articles

ISOPP: Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program

By ISOPP on 11th April 2022

The International Society of Oncology Pharmacy Practitioners (ISOPP) offers educational opportunities specific to the needs of oncology pharmacy practitioners worldwide.

 

Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program consists of 10 online courses (total of 25 hours) and an opportunity to meet at ISOPP’s 2023 Symposium in Spain to expand the Biosimilars Expert Network. Access to part 1 (Modules 1 to 4) is open!

  • Module 1 – Fundamentals of Biosimilars use in contemporary oncology clinical practice
  • Module 2 – Fundamentals in oncology pharmacy practice
  • Module 3 – Management of breast cancer
  • Module 4 – Management of colorectal cancer

If you completed the accredited version, you will receive a Certificate of Completion issued by the California Society of Health-System Pharmacists (CSHP), which will state the Continuing Education credits (25) earned. Visit www.isopp.org/opab for more information and spread the word using #ISOPPOPAB.

 

Registration is complimentary for ISOPP members.

Not a member? Join ISOPP! Note: You must be member of ISOPP in 2022 to be eligible for complimentary registration for both programs.

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article